Cytomegalovirus infection after lung transplantation

Abstract

Despite significant advances in treatment, cytomegalovirus (CMV) infection remains a major cause of morbidity after lung transplantation. Recently, there have been major developments in the management of CMV infection, which include the practical use of diagnostic methods such as the antigenemia assay that facilitate the early detection of CMV viremia and an oral CMV drug, valganciclovir. These advances have greatly changed post-transplant anti-CMV strategies and offer new insights. Herein, we report the updated worldwide practice on CMV prophylaxis and preemptive therapy after lung transplantation. We also provide some data on postoperative CMV infection and disease in our institution.